Policy / Pricing Erica Schwartz, ex-deputy surgeon general, picked to be next CDC director pharminent April 16, 2026
Clinical Data Lilly’s new obesity pill passes heart safety test in diabetes pharminent April 16, 2026
Clinical Data Lilly debuts more Foundayo data as FDA requests post-marketing trials pharminent April 16, 2026
Clinical Data Roche to start new Elevidys study following setback in Europe pharminent April 16, 2026
Clinical Data Lilly’s Foundayo posts ‘outstanding’ diabetes data, possibly easing FDA safety concerns pharminent April 16, 2026
M&A / Deals Obesity’s explosive growth continues as Q1 deals exceed total 2025 value pharminent April 16, 2026
Policy / Pricing FDA accelerated approval path needs improvement, says ICER pharminent April 16, 2026
Commercial Revolution doubles stock offering target to $2B following pancreatic cancer win pharminent April 16, 2026
M&A / Deals Terremoto wins $108m in Series C to drive cancer and rare disease programmes pharminent April 16, 2026
Clinical Data Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study pharminent April 16, 2026
Clinical Data Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study pharminent April 16, 2026
M&A / Deals Beeline, a Bain-backed biotech, debuts with immune drugs from Bristol Myers pharminent April 15, 2026
Regulatory FDA Approves Extended Dosing Interval for Regeneron’s EYLEA HD (aflibercept) pharminent April 15, 2026
Regulatory Lilly’s new obesity pill linked to ‘serious’ safety signals, FDA requests more data pharminent April 15, 2026
M&A / Deals Takeda continues to prune partnerships, cuts ties with mRNA-targeting Veritas In Silico pharminent April 15, 2026
M&A / Deals BMS makes a Beeline, bringing 5 assets to biotech’s $300M precision immunology debut pharminent April 15, 2026
Clinical Data S16 Ep52: Medical Crossfire: PD-L1 Inhibition in Advanced Cutaneous Squamous Cell Carcinoma — Mechanistic Rationale and Clinical Application pharminent April 15, 2026
Commercial With nearly a quarter billion in Q1, J&J targets $100B revenue in 2026 pharminent April 14, 2026
Manufacturing Lilly investing billions to prepare for overseas oral GLP-1 launches pharminent April 14, 2026
Regulatory FDA Issues Draft Guidance on Genome Editing Safety Standards to Advance Gene Therapy Development pharminent April 14, 2026
Market Access Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update pharminent April 14, 2026
